Bernhardt G. Zeiher, M.D., became an Abeona director on August 8, 2024. He brings more than 20 years of drug-development experience and oversaw the approval of 15 new treatments across serious diseases. Most recently he served as Chief Medical Officer of Astellas Pharma, where he led early- and late-stage drug development, medical and regulatory affairs, pharmacovigilance and quality assurance; he spent more than 10 years at Astellas, serving as CMO from 2018 to 2022. Earlier he led drug development at Pfizer, Eli Lilly and Company, and Merck, and practiced medicine in Indianapolis. He serves on the boards of Entrada Therapeutics, Inc. (Nasdaq: TRDA) and Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX). He received a B.S. in biology from the University of Toledo and an M.D. from Case Western Reserve University School of Medicine.